A Phase 3 interventional study of Bortezomib and Dexamethasone in Multiple Myeloma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 235 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-01.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.
Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 17th largest by enrollment of the 373 interventional ones that give a count, is one of 13 that started in 2007, is one of 53 in phase 3, and was the 58th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
University of Miami · Sites in United States
Ages 18+
Tanta University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
381 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 273 · Phase 3 57 · Phase 4 9
First in 1995; this study’s year is marked. 13 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 502 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 45 across the 373 interventional studies. Of the 225 that completed or were terminated, 118 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 381 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
54 studies in Multiple Myeloma by Takeda: 2 open now, 4 under way, 1 of them phase 3. Of 47 finished, 33 (70%) have results posted.
Among the 54 studies in Multiple Myeloma by Takeda, this one is the 7th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2007, is one of 11 in phase 3, and was the 7th registered.
Takeda’s Multiple Myeloma studies by the year they started, since 2002.
27 of the studies testing dexamethasone in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00572169Phase 3University of ArkansasUARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | 2027-08 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT05560399Icahn School of Medicine at Mount SinaiA Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | 2026-11 |
Add all 27 to your calendar (.ics) → With an account.
Among the 381 studies testing dexamethasone in Multiple Myeloma, from their registry updates:
Among Takeda’s 54 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have requiring systemic therapy. Measurable disease is defined by at least 1 of the following criteria:
Exclusion Criteria:
Any of the following clinical laboratory values within 21 days prior to enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
Drug: Bortezomib · Drug: Dexamethasone
Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance) .
Drug: Bortezomib · Drug: Dexamethasone · Drug: Thalidomide
Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
Drug: Bortezomib · Drug: Melphalan · Drug: Prednisone
Bortezomib bolus intravenous (IV) injection
Also known as: Velcade
Dexamethasone for oral administration
Melphalan for oral administration
Prednisone for oral administration
Thalidomide for oral administration
Progression Free Survival (PFS)
PFS is defined as the time from randomization to disease progression or death, whichever occurs first. Participants who did not progress and were still alive at the cut-off date were censored at the date of last contact. Response was assessed by the Investigator using the International Myeloma Working Group (IMWG) uniform response criteria. Progressive disease requires 1 of the following: * Increase of ≥ 25% from nadir in: * Serum M-component (absolute increase ≥ 0.5 g/dl) * Urine M-component (absolute increase ≥ 200 mg/24 hours) * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase \> 100 mg/dl) * Bone marrow plasma cell percentage (absolute % ≥ 10%) * Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas. * Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease
Time frame: From randomization until disease progression. Median follow-up time was 43 months.
Percentage of Participants With an Overall Response
Overall response defined as a best overall response of complete response (CR), very good partial response (VGPR) or partial response (PR), assessed by the Investigator using the IMWG uniform response criteria. CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours (h). PR requires 1 of the following: * ≥50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \<200 mg/24 h, or * If M-protein not measurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels, or * If FLC not measurable, a ≥ 50% reduction in plasma cells, provided baseline bone marrow plasma cell percentage was ≥30%. If present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.
Time frame: Response assessed every other cycle for up to 13 cycles (49 weeks).
Percentage of Participants With a Complete Response
Participants with a best overall response of complete response, defined as negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. Response was assessed by the Investigator using the IMWG uniform response criteria.
Time frame: Response assessed every other cycle, for up to 13 cycles (49 weeks).
Percentage of Participants With a Complete Response or a Very Good Partial Response
Complete response is defined by negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. Very good partial response is defined by serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours. Response was assessed by the Investigator using the IMWG uniform response criteria.
Time frame: Response assessed every other cycle for up to 13 cycles (49 weeks).
Duration of Response
Duration of response is defined in participants with an overall response as the time between first documentation of response and disease progression. Responders without disease progression were censored at the last clinical assessment of response.
Time frame: From first documented response until disease progression. Median follow-up time was 43 months.
Overall Survival
Overall survival is defined as the time between randomization and death. Participants still alive at the cutoff date or lost to follow-up were censored at the date of last contact.
Time frame: From randomization until death. Median follow-up time was 43 months.
Time to Alternative Therapy
Time to alternative therapy is defined as the time between randomization and alternative therapy. Participants who did not receive alternative therapy were censored at the time of last contact.
Time frame: From randomization until alternative therapy. Median follow-up time was 43 months.
Change From Baseline in EORTC QLQ-C30 - Global Health Status
The European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL Scale is scored between 0 and 100, where higher scores indicate better Global Health Status/QOL. Negative changes from baseline indicate deterioration in QOL or functioning and positive changes indicate improvement.
Time frame: Baseline and Day 1 of Cycles 3, 5, 7, 9, 11 and 13
Participants took part in the study at 158 investigative sites in the United States from 26 June 2007 to 28 March 2013
| Milestone | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| Started | 168 | 167 | 167 |
| Treated (safety population) | 165 | 158 | 163 |
| Completed 8 treatment cycles | 82 | 60 | 69 |
| Completed | 50 | 42 | 53 |
| Not completed | 118 | 125 | 114 |
| Withdrew: Adverse event | 58 | 67 | 65 |
| Withdrew: Protocol violation | 1 | 2 | 0 |
| Withdrew: Lack ofefficacy / physician decision | 7 | 7 | 8 |
| Withdrew: Progressive disease | 20 | 10 | 13 |
| Withdrew: Patient declined further treatment | 18 | 14 | 11 |
| Withdrew: Other | 11 | 16 | 13 |
| Withdrew: Did not receive study treatment | 3 | 9 | 4 |
PFS is defined as the time from randomization to disease progression or death, whichever occurs first. Participants who did not progress and were still alive at the cut-off date were censored at the date of last contact. Response was assessed by the Investigator using the International Myeloma Working Group (IMWG) uniform response criteria. Progressive disease requires 1 of the following: * Increase of ≥ 25% from nadir in: * Serum M-component (absolute increase ≥ 0.5 g/dl) * Urine M-component (absolute increase ≥ 200 mg/24 hours) * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase \> 100 mg/dl) * Bone marrow plasma cell percentage (absolute % ≥ 10%) * Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas. * Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease
| months | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| Progression Free Survival (PFS) | 14.7 (12.0 to 18.6) | 15.4 (12.6 to 24.2) | 17.3 (14.8 to 20.3) |
Overall response defined as a best overall response of complete response (CR), very good partial response (VGPR) or partial response (PR), assessed by the Investigator using the IMWG uniform response criteria. CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours (h). PR requires 1 of the following: * ≥50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \<200 mg/24 h, or * If M-protein not measurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels, or * If FLC not measurable, a ≥ 50% reduction in plasma cells, provided baseline bone marrow plasma cell percentage was ≥30%. If present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.
| percentage of participants | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| Percentage of Participants With an Overall Response | 73 | 80 | 70 |
Participants with a best overall response of complete response, defined as negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. Response was assessed by the Investigator using the IMWG uniform response criteria.
| percentage of participants | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| Percentage of Participants With a Complete Response | 3 | 4 | 4 |
Complete response is defined by negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. Very good partial response is defined by serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours. Response was assessed by the Investigator using the IMWG uniform response criteria.
| percentage of participants | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| Percentage of Participants With a Complete Response or a Very Good Partial Response | 37 | 51 | 41 |
Duration of response is defined in participants with an overall response as the time between first documentation of response and disease progression. Responders without disease progression were censored at the last clinical assessment of response.
| months | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| Duration of Response | 18.3 (14.3 to 24.2) | 22.4 (12.7 to 29.1) | 19.8 (16.4 to 23.3) |
Overall survival is defined as the time between randomization and death. Participants still alive at the cutoff date or lost to follow-up were censored at the date of last contact.
| months | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| Overall Survival | 49.8 (35.7 to NA) | 51.5 (38.5 to NA) | 53.1 (41.1 to NA) |
Time to alternative therapy is defined as the time between randomization and alternative therapy. Participants who did not receive alternative therapy were censored at the time of last contact.
| months | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| Time to Alternative Therapy | 19.7 (16.0 to 27.8) | 24.5 (16.6 to 27.6) | 19.0 (15.2 to 23.1) |
The European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL Scale is scored between 0 and 100, where higher scores indicate better Global Health Status/QOL. Negative changes from baseline indicate deterioration in QOL or functioning and positive changes indicate improvement.
| units on a scale | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| Cycle 3, Day 1 (n=129, 115, 125) | 1.3 ± 25.40 | -4.4 ± 27.04 | 2.0 ± 30.82 |
| Cycle 5, Day 1 (n=114, 98, 107) | -4.9 ± 30.36 | -6.1 ± 27.47 | -0.4 ± 29.24 |
| Cycle 7, Day 1 (n=89, 79, 84) | -3.3 ± 32.58 | -8.6 ± 31.86 | -4.7 ± 28.61 |
| Cycle 9, Day 1 (n=87, 66, 67) | -4.2 ± 33.55 | -8.1 ± 28.16 | -1.0 ± 28.55 |
| Cycle 11, Day 1 (n=71, 61, 65) | -11.6 ± 33.67 | -7.9 ± 29.54 | 2.8 ± 31.72 |
| Cycle 13, Day 1 (n=67, 52, 61) | -10.2 ± 36.00 | -8.5 ± 32.87 | 1.0 ± 35.16 |
Collected over Adverse events were collected from the first dose of study drug through 30 days after the last dose of study drug. Treatment was administered for up to 49 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bortezomib and Dexamethasone | — | 88/165 (53.3%) | 57/165 (34.5%) |
| Bortezomib, Thalidomide, and Dexamethasone | — | 92/158 (58.2%) | 68/158 (43%) |
| Bortezomib, Melphalan and Prednisone | — | 83/163 (50.9%) | 68/163 (41.7%) |
| Event | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| PneumoniaInfections and infestations | 18/165 | 12/158 | 10/163 |
| DiarrhoeaGastrointestinal disorders | 12/165 | 5/158 | 8/163 |
| DehydrationMetabolism and nutrition disorders | 8/165 | 6/158 | 9/163 |
| Cardiac failure congestiveCardiac disorders | 7/165 | 8/158 | 1/163 |
| Atrial fibrillationCardiac disorders | 7/165 | 7/158 | 1/163 |
| PyrexiaGeneral disorders | 7/165 | 2/158 | 2/163 |
| Deep vein thrombosisVascular disorders | 7/165 | 4/158 | 2/163 |
| AnaemiaBlood and lymphatic system disorders | 4/165 | 6/158 | 2/163 |
| VomitingGastrointestinal disorders | 3/165 | 5/158 | 6/163 |
| HypotensionVascular disorders | 3/165 | 3/158 | 6/163 |
| Event | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone |
|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 2/165 | 1/158 | 12/163 |
| InsomniaPsychiatric disorders | 9/165 | 6/158 | 6/163 |
| HyperuricaemiaMetabolism and nutrition disorders | 3/165 | 8/158 | 4/163 |
| Platelet count decreasedInvestigations | 3/165 | 1/158 | 7/163 |
| Weight decreasedInvestigations | 4/165 | 2/158 | 6/163 |
| Neutrophil count decreasedInvestigations | 0/165 | 0/158 | 6/163 |
| Rash pruriticSkin and subcutaneous tissue disorders | 0/165 | 5/158 | 3/163 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/165 | 5/158 | 3/163 |
| Vision blurredEye disorders | 3/165 | 5/158 | 1/163 |
| DysgeusiaNervous system disorders | 2/165 | 4/158 | 2/163 |
Intention to treat population, defined as all participants randomized
| Age, Continuous(years) | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone | Total |
|---|---|---|---|---|
| Mean | 72.6 ± 9.35 | 71.3 ± 8.73 | 71.3 ± 8.67 | 71.7 ± 8.92 |
| Age, Customized(participants) | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone | Total |
|---|---|---|---|---|
| ≥ 65 years | 140 | 135 | 139 | 414 |
| ≥ 75 years | 84 | 64 | 62 | 210 |
| ≥ 80 years | 40 | 27 | 23 | 90 |
| Sex: Female, Male(Participants) | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone | Total |
|---|---|---|---|---|
| Female | 67 | 97 | 77 | 241 |
| Male | 101 | 70 | 90 | 261 |
| Race/Ethnicity, Customized(participants) | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone | Total |
|---|---|---|---|---|
| White | 131 | 124 | 118 | 373 |
| Black | 23 | 31 | 29 | 83 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 2 | 2 |
| Asian | 2 | 1 | 0 | 3 |
| American Indian or Alaskan Native | 0 | 1 | 2 | 3 |
| Other | 10 | 10 | 15 | 35 |
| Not Reported | 2 | 0 | 1 | 3 |
| Region of Enrollment(participants) | Bortezomib and Dexamethasone | Bortezomib, Thalidomide, and Dexamethasone | Bortezomib, Melphalan and Prednisone | Total |
|---|---|---|---|---|
| United States | 168 | 167 | 167 | 502 |
Showing the first 100 of 235 sites across 2 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2007, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Melphalan · Prednisone · Thalidomide
Millennium Pharmaceuticals, Inc. →